Foghorn Therapeutics Inc. – Filings and Transcripts

NASDAQ: FHTX
Share price (9/29/26): $3.52
Market cap (9/29/26): $209 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 06/30/26 Q2

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

Prospectuses and Registrations Filter

Registration of securities for employees

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Shelf registration

Registration of securities for employees

Ownership Filter

Mendelsohn Michael

Cole Douglas G.

News Filter

Provides Second Quarter 2026 Financial and Corporate Update

Shareholder Vote Results

Provides First Quarter 2026 Financial and Corporate Update

Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Provides Financial Update for 2025 and 2026 Strategic Outlook FHD-909 (LY4050784) Phase 1 Dose-Escalation Advancing as Planned, Targeting SMARCA4 (BRG1)-mutant Cancers With a Focus on Non-Small Cell Lung Cancer

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Other Filter

Scanned paper annual report submission

Scanned paper annual report submission

Notice of effectiveness

Correspondence with the SEC

Letter from the SEC